Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

188Re-ZHER2:V2, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment.

Author:
  • Mohamed Altai
  • Helena Wållberg
  • Hadis Honarvar
  • Joanna Strand
  • Anna Orlova
  • Zohreh Varasteh
  • Mattias Sandström
  • John Löfblom
  • Erik Larsson
  • Sven-Erik Strand
  • Mark Lubberink
  • Stefan Ståhl
  • Vladimir Tolmachev
Publishing year: 2014
Language: English
Pages: 1842-1848
Publication/Series: Journal of Nuclear Medicine
Volume: 55
Issue: 11
Document type: Journal article
Publisher: Society of Nuclear Medicine

Abstract english

Affibody molecules are small (7 kDa) nonimmunoglobulin scaffold proteins with favorable tumor-targeting properties. Studies concerning the influence of chelators on biodistribution of (99m)Tc-labeled Affibody molecules demonstrated that the variant with a C-terminal glycyl-glycyl-glycyl-cysteine peptide-based chelator (designated ZHER2:V2) has the best biodistribution profile in vivo and the lowest renal retention of radioactivity. The aim of this study was to evaluate (188)Re-ZHER2:V2 as a potential candidate for radionuclide therapy of human epidermal growth factor receptor type 2 (HER2)-expressing tumors.

Keywords

  • Radiology, Nuclear Medicine and Medical Imaging

Other

Published
  • ISSN: 0161-5505
Sven-Erik Strand
E-mail: sven-erik.strand [at] med.lu.se

Project manager

Systemic Radiation Therapy Group

32

Professor emeritus

Medical Radiation Physics, Lund

32